# Evaluation of D-Fi for the Treatment of Wounds Due to DEB

> **NCT06892639** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Castle Creek Biosciences, LLC.** · enrollment: 32 (estimated)

## Conditions studied

- Dystrophic Epidermolysis Bullosa

## Interventions

- **BIOLOGICAL:** D-Fi

## Key facts

- **NCT ID:** NCT06892639
- **Lead sponsor:** Castle Creek Biosciences, LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-03-27
- **Primary completion:** 2027-09
- **Final completion:** 2042-02
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06892639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06892639, "Evaluation of D-Fi for the Treatment of Wounds Due to DEB". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT06892639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*